LY4086940 for Obesity
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot have used weight loss medications in the 3 months before screening.
How does the drug LY4086940 for obesity differ from other treatments?
The drug LY4086940 for obesity is unique because it may target specific genetic or metabolic pathways involved in obesity, unlike existing treatments that primarily focus on appetite suppression or nutrient absorption. This approach could offer a more personalized treatment option based on an individual's genetic makeup.12345
What is the purpose of this trial?
The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body.Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 9 visits.
Research Team
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Eligibility Criteria
This trial is for healthy individuals, as well as those with overweight or obesity, which may include people with type 2 diabetes. Participants will be involved in the study for about 10 to 15 weeks and must attend up to 9 visits.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment Part A
Participants receive either a single dose or multiple doses of LY4086940 or placebo orally
Treatment Parts B, C, D
Participants receive multiple doses of LY4086940 or placebo orally
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- LY4086940
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University